-+ 0.00%
-+ 0.00%
-+ 0.00%
Harvard Bioscience raises FY2026 revenue growth outlook to 3%-5%
Share
Listen to the news
Harvard Bioscience raises FY2026 revenue growth outlook to 3%-5%
  • Harvard Apparatus Regenerative Technology raised full-year 2026 revenue guidance to 3%-5% year-over-year growth.
  • Adjusted gross margin expected at 57%-59%, reflecting higher volume of lower-margin CMT products, plus geographic mix.
  • Adjusted EBITDA growth forecast at 6%-10%; target maintained as sales momentum offsets mix-related margin pressure.
  • Third-quarter revenue outlook set at USD 21 million-USD 22.6 million; adjusted EBITDA seen at USD 1.5 million-USD 2.5 million.
  • Guidance follows second-quarter revenue of USD 22.7 million, up 11% year over year; adjusted EBITDA rose to USD 1.7 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Apparatus Regenerative Technology Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending